Stability of the ready-to-use solutions of eribulin for intravenous infusion

Annales Pharmaceutiques Francaises

Volumn 70, Issue 5, 2012, Pages 249-255

  Poujol, S ^a   Dell'ova, M ^a   Bekhtari, K ^a   Bressolle, F ^a,b   Pinguet, F ^a  

^a CENTRE VAL D AURELLE   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Different storage conditions; Eribulin; HPLC UV; Polyolefin bags; Polypropylene syringe; Stability; Stress conditions

Indexed keywords

ERIBULIN; POLYOLEFIN; POLYPROPYLENE; SODIUM CHLORIDE;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG HYDROLYSIS; DRUG OXIDATION; DRUG RETENTION; DRUG STABILITY; DRUG STORAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIGHT EXPOSURE; PHOTOLYSIS; REFRIGERATOR; SUNLIGHT PROTECTION; SYRINGE;

CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FURANS; INDICATORS AND REAGENTS; INFUSIONS, INTRAVENOUS; KETONES; PHARMACEUTICAL SOLUTIONS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84866917292     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2012.06.004     Document Type: Article

References (15)

1. Towle M.J., Salvato K.A., Budrow J., Wels B.F., Kuznetsov G., Aalfs K.K., et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin. Cancer Res 2001, 61:1013-1021.
2. Yu M.J., Kishi Y., Littlefield B.A. Discovery of E7389, a fully synthetic macrocyclic ketone analogue of halichondrin B. Anticancer agents from natural products 2005, Taylor & Francis, Washington, DC. D.J. Newman, D.G.I. Kingston, G.M. Cragg (Eds.).
3. Hirata Y., Uemura D. Halichondrins - antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986, 58:701-710.
4. Bai R.L., Paull K.D., Herald C.L., Malspeis L., Pettit G.R., Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991, 266:15882-15889.
5. Jordan M.A., Kamath K., Manna T., Okouneva T., Miller H.P., Davis C., et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005, 4:1086-1095.
6. Okouneva T., Azarenko O., Wilson L., Littlefield B.A. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008, 7:2003-2011.
7. Smith J.A., Wilson L., Azarenko O., Zhu X., Lewis B.M., Littlefield B.A., et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010, 49:331-337.
8. Kuznetsov G., Towle M.J., Cheng H., Kawamura T., TenDyke K., Liu D., et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004, 64:5760-5766.
9. Towle M.J., Salvato K.A., Wels B.F., Aalfs K.K., Zheng W., Seletsky B.M., et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 2011, 71:496-500.
10. Cortes J., O'Shaughnessy J., Loesch D., Blum J.L., Vahdat L.T., Petrakova K., et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011, 377:914-923.
11. Eribulin approved for late-stage breast cancer. Oncology Times 2010;32:9 . [Assessed February, 23, 2012]. http://journals.lww.com/oncology-times/Fulltext/2010/12100/Eribulin_Approved_for_Late_Stage_Breast_Cancer.12.aspx.
12. Jain S., Cigler T. Eribulin mesylate in the treatment of metastatic breast cancer. Biologics 2012, 6:21-29.
13. Bardin C., Astier A., Vulto A., Sewell G., Vigneron J., Trittler R., et al. Guidelines for the practical stability studies of anticancer drugs: a European consensus conference. Ann Pharm Fr 2011, 69:221-231.
14. WHO guidelines for stability testing of pharmaceutical products containing well established drug substances in conventional dosage forms [Assessed February 2012]. http://apps.who.int/medicinedocs/en/d/Js5517e/12.html.
15. Tab stability (Q1A-Q1F) on Quality Guidelines//ICH Guidelines [Assessed February, 23, 2012]. http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.